Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Reliability of Unsupervised Digital Cognitive Assessment in a Large Adult Population Across the Aging Lifespan from INTUITION: A Brain Health Study
Aging, Dementia, Cognitive, and Behavioral Neurology
S8 - Behavioral and Cognitive Neurology (5:06 PM-5:18 PM)
009

Mobile and remote cognitive assessments may expedite patient screening for populations vulnerable to accelerated brain aging. As access to personal electronics increases, the modalities for data collection widen. Emerging evidence supports the case for the feasibility and validity of remote, digital cognitive assessments. However, test-retest reliability remains unknown in unsupervised settings and when performed at scale in diverse, heterogenous populations.  

To assess the feasibility and reliability of an unsupervised, digital cognitive battery performed by participants enrolled in the INTUITION (NCT05058950) study, who represent a U.S. adult population at-risk for cognitive decline. 

The INTUITION study is an observational two-year virtual study of 23,000 adults across the aging lifespan. Participants complete a monthly web-based 30-minute digital cognitive battery on a personal computing device. The assessment contains five tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB), which is designed to interrogate performance on specific cognitive domains, including attention, executive function, and episodic memory. We assessed test-retest reliability for key cognitive outcome variables with Pearson and intra-class correlations. 
The INTUITION study was 91% enrolled (N=20,916) as of September 2022. N=9,415 participants have provided at least 5 sequential CANTAB assessments. Moderate-to-high test-retest reliability was observed for key outcome variables (range; r=0.42-0.80). Subtle, but measurable learning effects were noted across initial sessions and then abated alongside rising performance reliability following subsequent assessments. We present detailed test-retest reliabilities for representative outcomes of each CANTAB assessment from the total study population and by cohort.  
We demonstrated moderate-to-strong reliability in key cognitive outcome measures and reliability increased as a function of age. Reliability findings were comparable to those reported in the literature for supervised cognitive assessments. These initial results suggest remote and unsupervised cognitive testing is plausible and sufficiently reliable and can be self-administered in ecologically valid real-world settings. 
Authors/Disclosures
Michael G. Erkkinen, MD (Brigham and Women's Hospital)
PRESENTER
Dr. Erkkinen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen.
Monroe Butler, MD,PhD Dr. Butler has received personal compensation for serving as an employee of Biogen. Dr. Butler has stock in Biogen.
Roland Brown, PhD Dr. Brown has received personal compensation for serving as an employee of Biogen. Dr. Brown has stock in Biogen.
Matt Hobbs (Biogen) Mr. Hobbs has received personal compensation for serving as an employee of Biogen. Mr. Hobbs has stock in Biogen.
Audrey Gabelle, MD (Hospital Gui De Chauliac) No disclosure on file
Andrew Becker, PhD (Biogen) Dr. Becker has received personal compensation for serving as an employee of Biogen.
Paramita Saha-Chaudhuri, PhD Dr. Saha-Chaudhuri has received personal compensation for serving as an employee of Biogen. Dr. Saha-Chaudhuri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Saha-Chaudhuri has stock in Biogen.
Jessica Ash, PhD (Biogen) Dr. Ash has received personal compensation for serving as an employee of Biogen.
Sean Kenny, MBA (Biogen) Mr. Kenny has received personal compensation for serving as an employee of Biogen. Mr. Kenny has stock in Biogen.
Hanson Lenyoun, MD Dr. Lenyoun has received personal compensation for serving as an employee of Apple. Dr. Lenyoun has stock in Apple.
Matt T. Bianchi, MD, PhD No disclosure on file
Shibeshih Belachew, MD Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.